Evidence mapPaperPMID 34209677Full record

ReviewNutrients2021

Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders.

Giorgia Sebastiani, Laura Almeida-Toledano, Mariona Serra-Delgado, Elisabet Navarro-Tapia, Sebastian Sailer, Olga Valverde, Oscar Garcia-Algar, Vicente Andreu-Fernández

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Plants (Basel, Switzerland) · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Giorgia SebastianiDepartment of Neonatology, Hospital Clínic-Maternitat, ICGON, BCNatal, 08028 Barcelona, Spain.
Laura Almeida-ToledanoInstitut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain.ORCID 0000-0002-9263-7222
Mariona Serra-DelgadoInstitut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain.
Elisabet Navarro-TapiaGrup de Recerca Infancia i Entorn (GRIE), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0002-0127-7365
Sebastian SailerDepartment of Neonatology, Hospital Clínic-Maternitat, ICGON, BCNatal, 08028 Barcelona, Spain.
Olga ValverdeNeurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.ORCID 0000-0003-2264-7852
Oscar Garcia-AlgarDepartment of Neonatology, Hospital Clínic-Maternitat, ICGON, BCNatal, 08028 Barcelona, Spain.ORCID 0000-0001-5708-4362
Vicente Andreu-FernándezGrup de Recerca Infancia i Entorn (GRIE), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0001-7183-8706
Hospital Sant Joan de Déu Barcelona · ESHospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversitat Pompeu Fabra · ESValencian International University · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, neurological and neurodegenerative disorders research has focused on altered molecular mechanisms in search of potential pharmacological targets, e.g., imbalances in mechanisms of response to oxidative stress, inflammation, apoptosis, autophagy, proliferation, differentiation, migration, and neuronal plasticity, which occur in less common neurological and neurodegenerative pathologies (Huntington disease, multiple sclerosis, fetal alcohol spectrum disorders, and Down syndrome). Here, we assess the effects of different catechins (particularly of epigalocatechin-3-gallate, EGCG) on these disorders, as well as their use in attenuating age-related cognitive decline in healthy individuals. Antioxidant and free radical scavenging properties of EGCG -due to their phenolic hydroxyl groups-, as well as its immunomodulatory, neuritogenic, and autophagic characteristics, makes this catechin a promising tool against neuroinflammation and microglia activation, common in these pathologies. Although EGCG promotes the inhibition of protein aggregation in experimental Huntington disease studies and improves the clinical severity in multiple sclerosis in animal models, its efficacy in humans remains controversial. EGCG may normalize DYRK1A (involved in neural plasticity) overproduction in Down syndrome, improving behavioral and neural phenotypes. In neurological pathologies caused by environmental agents, such as FASD, EGCG enhances antioxidant defense and regulates placental angiogenesis and neurodevelopmental processes. As demonstrated in animal models, catechins attenuate age-related cognitive decline, which results in improvements in long-term outcomes and working memory, reduction of hippocampal neuroinflammation, and enhancement of neuronal plasticity; however, further studies are needed. Catechins are valuable compounds for treating and preventing certain neurodegenerative and neurological diseases of genetic and environmental origin. However, the use of different doses of green tea extracts and EGCG makes it difficult to reach consistent conclusions for different populations.

Indexed as

AdultAgedAged, 80 and overAnimalsAntioxidantsCatechinCognitive AgingFemaleHumansMaleMiddle AgedNervous System DiseasesNeurodegenerative DiseasesNeuronal PlasticityNeuroprotective AgentsAntioxidantsCatechinNeuroprotective Agentsage-related cognitive declineantioxidantcatechinsDown syndromeepigallocatechin-3-gallatefetal alcohol spectrum disordersmultiple sclerosisneurodegenerative disordersneurological disorders

Identifiers

PMID34209677
PMCPMC8308206
OpenAlexW3174181537

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.